Premium
Variability in immunophenotype in diffuse large B‐cell lymphoma and its clinical relevance
Author(s) -
De Leval L,
Harris N L
Publication year - 2003
Publication title -
histopathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.626
H-Index - 124
eISSN - 1365-2559
pISSN - 0309-0167
DOI - 10.1111/j.1365-2559.2003.01758.x
Subject(s) - immunophenotyping , lymphoma , pathology , histogenesis , diffuse large b cell lymphoma , biology , clinical significance , immunohistochemistry , medicine , immunology , antigen
Diffuse large B‐cell lymphoma (DLBCL), the single largest category of lymphoma, is a clinically and biologically heterogeneous disease entity. Clinically, patients differ in their mode of presentation and respond variably to therapy. A combination of clinical parameters can be used to predict the patient's response to therapy and survival. The pathological variability of DLBCL is expressed in morphology, immunophenotype, cytogenetic and molecular genetic features. Numerous markers detectable by immunohistochemistry and linked to different aspects of tumour biology have been studied in DLBCL, including lineage‐associated and immune markers, proliferation and apoptosis markers, cell adhesion molecules, and more recently stage‐specific markers of B‐cell differentiation. This review summarizes these studies in regard to their clinical significance and in the light of recent advances in our understanding of the molecular pathology and histogenesis of DLBCL.